Amoy Diagnostics Co Ltd
SZSE:300685

Watchlist Manager
Amoy Diagnostics Co Ltd Logo
Amoy Diagnostics Co Ltd
SZSE:300685
Watchlist
Price: 26.13 CNY -3.51% Market Closed
Market Cap: 10.2B CNY
Have any thoughts about
Amoy Diagnostics Co Ltd?
Write Note

EV/EBIT
Enterprise Value to EBIT

31.2
Current
45.3
Median
3.8
Industry
Lower than median
Higher than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
31.2
=
Enterprise Value
9.4B CNY
/
EBIT
300.3m CNY
All Countries
Close
EBIT Growth
CN
Amoy Diagnostics Co Ltd
SZSE:300685
Average EV/EBIT: 24.4
31.2
75%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -214 322.8 N/A
US
Abbvie Inc
NYSE:ABBV
22.8
88%
US
Amgen Inc
NASDAQ:AMGN
33.1
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.1
44%
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -507.3 N/A
AU
CSL Ltd
ASX:CSL
25.9
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.4
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.1 N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
27.8
2-Years Forward
EV/EBIT
22.6
3-Years Forward
EV/EBIT
18.3

See Also

Discover More